Characterization of ABL exon 7 deletion by molecular genetic and bioinformatic methods reveals no association with imatinib resistance in chronic myeloid leukemia.
In chronic myeloid leukemia (CML), the best characterized imatinib resistance mechanisms are BCR-ABL tyrosine kinase domain mutations and clonal evolution, but recently alternative splicing of BCR-ABL was also proposed as a mechanism for imatinib resistance. Among recently reported BCR-ABL splice variants, exon 7 deletion (Δexon7) was characterized in this study. The frequency of Δexon7 was investigated in 30 healthy controls and in 76 CML patients at different time points of the disease course by four different molecular genetic methods (direct sequencing, fragment analysis, allele-specific and quantitative PCR). The functionality and viability of the variant protein was tested by bioinformatic prediction. The Δexon7 was abundantly detected with similar frequency in healthy controls, in imatinib naive and resistant CML patients on BCR-ABL and also on the nontranslocated ABL. The detection rate of Δexon7 (varying between 17 and 100%) was highly dependent on the expression levels of BCR-ABL or ABL and the sensitivity of detection method. According to secondary structure prediction by bioinformatic methods, the exon 7 deleted mRNA is a target for nonsense-mediated decay, and the translated protein is likely to be nonfunctional and unstable. Taken together all the above observations, we concluded that Δexon7 is a common splice variant not associating with imatinib resistance.
Laboratory of Molecular Diagnostics, Hungarian National Blood Transfusion Service, Karolina str 19-21, Budapest 1113, Hungary. nora.meggyesi@kkk.org.hu
Nóra
N
Meggyesi
Lajos
L
Kalmár
Sándor
S
Fekete
Tamás
T
Masszi
Attila
A
Tordai
Hajnalka
H
Andrikovics
D000595:Amino Acid Sequence; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001549:Benzamides / Q000627:therapeutic use*; D019295:Computational Biology; D019008:Drug Resistance, Neoplasm / Q000235:genetics*; D005091:Exons / Q000235:genetics; D017353:Gene Deletion; D016313:Genes, abl / Q000235:genetics*; D006801:Humans; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy / Q000235:genetics*; D008967:Molecular Biology; D008969:Molecular Sequence Data; D010879:Piperazines / Q000627:therapeutic use*; D016133:Polymerase Chain Reaction; D020033:Protein Isoforms; D017433:Protein Structure, Secondary; D016315:Proto-Oncogene Proteins c-abl / Q000737:chemistry / Q000235:genetics; D011743:Pyrimidines / Q000627:therapeutic use*; D017384:Sequence Deletion
D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D020033:Protein Isoforms; D011743:Pyrimidines; D000068877:Imatinib Mesylate; D016315:Proto-Oncogene Proteins c-abl